



**EXECUTIVE COMMITTEE MEMBERS,
DEPARTMENT/PROGRAMME COORDINATORS and
SCIENTIFIC COMMITTEE MEMBERS**

**DISCLOSURE OF POTENTIAL CONFLICT OF INTEREST
2017**

ESO's initiatives and activities are defined by the ESO Executive Committee, the Scientific Committee and by the Department/Programme Coordinators.

For transparency, the ESO core collaborators declare potential conflict of interest that might rise in general when programmes are defined and developed.

We consider as potential conflict of interest any of the following:

- Active role in committees or at managerial level with other organisations.
- Any financial interest in or arrangement with a company whose products or services might be involved when proposing an activity, or included in the contents of a proposed activity
- Any financial interest in or arrangement with a competing company.
- Any other financial relationship, direct or indirect, or other situations that might raise the question of bias in proposing and developing activities, including pertinent commercial or other sources of funding for the person or for the associated department or organisation, personal relationships or direct academic competition.

Matti Aapro: In charge of International relations for the Genolier Cancer Center. He is a Board member of ECCO (European CanCer Organisation). He serves the International Society for Geriatric Oncology (SIOG) as Executive Board Member. He is past-President of the Multinational Association for Supportive Care in Cancer (MASCC) and member of several Committees of MASCC. He is President of Honour of the French-speaking Society for Supportive Care (AFSOS), as well as Advisor to the Japanese Association for Supportive Care in Cancer (JASCC). He has been member of the Board of the European Organization for Research and Treatment of Cancer (EORTC) and has various roles in Scientific Committees of the European Society of Medical Oncology (ESMO).

Is/was a consultant for Amgen, BMS, Celgene, Clinigen, Eisai, Genomic Health, GSK, Helsinn, Hospira, JnJ, Novartis, Merck, Merck Serono, Pfizer, Pierre Fabre, Roche, Sandoz, Tesaro, Teva, Vifor, Received honoraria for lectures at symposia of Amgen, Bayer Schering, Biocon, Cephalon, Chugai, DRL, Eisai, Genomic Health, GSK, Helsinn, Hospira, Ipsen, JnJ OrthoBiotech, Kyowa Hakko Kirin, Merck, Merck Serono, Novartis, Ono Pharmaceuticals, Pfizer, Pierre Fabre, Roche, Sandoz, Sanofi, Tesaro, Taiho, Teva, Vifor

Adriana Albini: No significant relationships

Felipe Calvo: No significant relationships

Paolo G. Casali: His institution received funds for research from Amgen Dompé, Bayer, Eli Lilly, Daiichi Sankyo Pharma, Epizyme Inc., Glaxo SK, Novartis, Pfizer, PharmaMar, Receipt of honoraria for consultancy/advisory role and/or for lectures from Bayer, Blueprint Medicines, Eisai, Eli Lilly, Glaxo SK, Merck SD, Merck Serono, Nektar Ther., Novartis, Pfizer, PharmaMar

Franco Cavalli: Advisory Committee of Gilead, receipt of grants/research supports from Gilead, Roche, receipt of honoraria or consultation fees from Novartis, Abbvie

Fatima Cardoso: Receipt of honoraria or consultation fees from Astellas/Medivation, Astra Zeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline, MacroGenics, Merck-Sharp, Merus BV, Novartis, Pfizer, Pierre-Fabre, Roche, Sanofi, Teva

Alberto Costa: Advisor Cloud Pathology Group (digital pathology)

Alexander M.M. Eggermont: ESMO Executive Board Member, CRUK Member Board of Trustees, Receipt of honoraria or consultation fees from Actelion, Agenus, Bayer, BMS, GSK, HaliuDx, Incyte, Merck, MSD, Nektar, Novartis, Sanofi

Alexander Eniu: ESMO Executive Board Member, Chair ASCO International Affairs Committee, Receipt of grants/research supports from Astra Zeneca and Roche

Enriqueta Felip: Receipt of honoraria or consultation fees from Eli Lilly, Pfizer, Roche, Boehringer Ingelheim, MSD, Participation in a sponsored speakers' bureau of Astra Zeneca, BMS, Novartis

Stan Kaye: No significant relationships

Peter Naredi: President European Cancer Organisation (ECCO), Chair Acta Chirurgica Scandinavica, Council Member British Journal of Surgery Society

Larry Norton: Stock shareholder of Samus Therapeutics

Nicholas Pavlidis: No significant relationships

Fedro A. Peccatori: No significant relationships

Christian Rolfo: Realtime Oncology (Oncompass) Steering Committee, Mylan Scientific Advisor, Receipt of grants/research supports from Sanofi, Participation in a sponsored speakers' bureau of Novartis

Marco Siano: Receipt of grants/research supports from MSD, BMS, Merck Group, Eisai, Bayer, Participation in a sponsored speakers' bureau of Eisai

Lena Sharp: President Elect and Board Member of EONS

Stephan Stilgenbauer: Receipt of grants/research supports from Abbvie, Amgen, Boehringer-Ingelheim, Celgene, Genentech, Genzyme, Gilead, GSK, Janssen, Mundipharma, Novartis, Pharmacyclics, Hoffmann-La Roche, Sanofi

Riccardo Valdagni: Scientific Advisory Board of Bayer

Eric P. Winer: No significant relationships

Paul Workman: CEO The Institute of Cancer Research Board of Trustees, Non-Exec Director Royal Marsden NHS Foundation Trust, Director Cancer Research UK Centre, ICR and RMH, Director Cancer Research Centre of Excellence, ICR & Imperial College, Chair Structural Genomics Consortium, Deputy Editor Molecular Cancer Therapeutics, Review Editor Cancer Cell, Receipt of grants/research supports from Piramed, Chroma, Vernalis, Astex, Astra Zeneca, Merck Serono, Sareum, Jansen, Pioneer Fund, BACIT, Cyclacel, Receipt of honoraria or consultation fees from Piramed, Chroma, Novartis, Astex, Nextech, NuEvolution, Astra Zeneca, Cyclacel, Stock shareholder of Piramed, Chroma, Nextech

David Zaridze: No significant relationships

Emanuele Zucca: Receipt of grants/research supports from Celgene, Mundipharma, Roche, J&J, Merck, Receipt of honoraria or consultation fees from Gilead, Roche, J&J (Janssen), Bayer